The government of Barbados has introduced landmark legislation to the Senate that will overhaul the country’s decades-old drug regulatory system, laying the groundwork for a new independent authority designed to boost oversight, expand access to critical medical products, and build a domestic and regional pharmaceutical sector.
Senator Jerome Walcott, Senior Minister coordinating Social and Environmental Policy and leading the Social Sector Reform initiative, presented the Barbados Medical Products Bill to the upper legislative chamber on Wednesday. He framed the proposal as the most transformative update to the island nation’s drug regulation framework since the Barbados Drug Service was founded in 1980. Under the plan, the newly created Barbados Medical Products Authority (BMPA) will operate as a modern, self-governing regulatory body with jurisdiction over all medicines, medical devices, and related health products distributed and used across Barbados.
“This new body will serve as a modern, autonomous national regulator tasked with overseeing all medical products and guaranteeing that every product available to Barbadians meets strict international benchmarks for quality, safety, and therapeutic effectiveness,” Walcott explained. A former health minister, Walcott added that the BMPA will deliver three core public and economic benefits: it will expand access to proven safe and effective medications, strengthen national public health safeguards, and create a supportive regulatory environment for pharmaceutical manufacturing, research, and the broader life sciences industry. The bill is a central plank of the government’s broader push to modernize the national health regulatory ecosystem and establish Barbados as a leading center for regulatory science across the Caribbean region.
Walcott traced the impetus for the reform to critical gaps exposed by the COVID-19 pandemic, when small developing nations around the globe faced crippling barriers accessing life-saving vaccines, drugs, and medical supplies. “The pandemic laid bare deep inequities in access to vaccines, pharmaceuticals, medical devices, even basic supplies like nasal swabs,” Walcott said. “We had the resources, we were ready to purchase critical supplies, but producing and exporting nations simply could not prioritize us for delivery.” This experience pushed the Barbados government to prioritize reducing the country’s vulnerability to future global supply chain disruptions, he noted.
Plans for the reform were further refined following discussions with Rwandan President Paul Kagame during his official visit to Barbados in April 2022. During those talks, Kagame shared Rwanda’s strategy to build domestic vaccine and pharmaceutical manufacturing capacity, including its high-profile partnership with German biotechnology firm BioNTech to produce messenger RNA (mRNA) vaccines. “That conversation directly sparked our interest in pursuing a similar path here in Barbados,” Walcott said.
Following that meeting, Barbados developed a formal, long-term strategy to grow its domestic pharmaceutical industry. With funding and support from the Susan Thomas Buffett Foundation, the government began work on a foundational policy white paper and the development of a robust, internationally aligned regulatory framework. Walcott explained that global standards require nations to reach World Health Organization (WHO) Regulatory Maturity Level 3 before they can qualify for large-scale, internationally recognized pharmaceutical manufacturing, a benchmark Barbados has not yet hit. “Right now, our regulatory system is still in the early stages; we are currently at Level 1,” he said.
The final legislation that reached the Senate this week was shaped by months of extensive stakeholder consultations, targeted technical assistance, and specialized training programs. The European Union provided critical development support for the initiative, while Rwandan government officials and legal experts shared hands-on experience building their own national regulatory framework, helping Barbados avoid common pitfalls in the process. In addition to the new regulatory authority, the government has already established Barbados Pharmaceutical Inc., a state-owned entity that marks another key milestone in preparing the country for future manufacturing operations.
One of the BMPA’s core new responsibilities will be handling marketing authorization for all medical products, a function currently managed by the existing Barbados Drug Service. Walcott acknowledged that the government’s goal of reaching WHO Maturity Level 3 by 2028 is an ambitious target, but emphasized that the administration is committed to advancing the reform as quickly and effectively as possible to unlock the economic and public health benefits of a robust domestic pharmaceutical sector.